Rheumatoid Arthritis study: Glucocorticoid
Official title Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares
ClinicalTrials.gov ID: NCT07245732
What this study is testing
What is Glucocorticoid (GC)?
Glucocorticoid (GC) is an investigational medicine, given as a once-daily injection into a muscle, being studied as a potential treatment for rheumatoid arthritis (ra).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if one injection of steroid medicine relieves flare symptoms, improves daily function, and satisfies patients as much as taking pills for three weeks. It also asks participants how they feel about the treatment.
- Who it's for
- Adults with rheumatoid arthritis who are currently having a flare (at least three swollen and tender joints) and who have not used steroids in the past month.
- What's involved
- Participants are randomly assigned to receive either one muscle injection of methylprednisolone 120 mg or oral prednisone tablets that start at 15 mg daily and taper over three weeks. They complete questionnaires about symptoms, function, and satisfaction, and a small group also takes part in an interview.
- Time commitment
- The study lasts about six weeks, with an initial visit for treatment and follow‑up visits (including questionnaires) through week 6, plus a possible interview for some participants.
- Phase 4: studies an already-approved treatment
- Time commitment: about 3 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Rheumatologist verified RA diagnosis.
- Patients are allowed to be on non-steroidal anti-inflammatory drugs (NSAIDs) prior to randomization, but the dosages must be stable for ≥2 weeks...
- Patients must be on stable doses of conventional synthetic disease-modifying antirheumatic drugs (csDMARD)/targeted synthetic disease-modifying...
You likely can't join if
- Allergies, intolerances or contraindications to systemic GCs or IM injections
- Patients with active malignancy, are pregnant or breastfeeding.
- Patients who have received systemic or intra-articular GC within 4-weeks of randomization.
The study team makes the final eligibility decision.
Where it is enrolling
- Toronto, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 3 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Toronto, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.